Cargando…
Current status of photodynamic technology for urothelial cancer
5‐Aminolevulinic acid is a new‐generation photosensitizer with high tumor specificity. It has been used successfully in the diagnosis, treatment, and screening of urological cancers including bladder cancer; specifically, it has been used in photodynamic diagnosis to detect tumors by illuminating th...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819295/ https://www.ncbi.nlm.nih.gov/pubmed/34750935 http://dx.doi.org/10.1111/cas.15193 |
_version_ | 1784646029375700992 |
---|---|
author | Inoue, Keiji Fukuhara, Hideo Yamamoto, Shinkuro Karashima, Takashi Kurabayashi, Atsushi Furihata, Mutsuo Hanazaki, Kazuhiro Lai, Hung Wei Ogura, Shun‐Ichiro |
author_facet | Inoue, Keiji Fukuhara, Hideo Yamamoto, Shinkuro Karashima, Takashi Kurabayashi, Atsushi Furihata, Mutsuo Hanazaki, Kazuhiro Lai, Hung Wei Ogura, Shun‐Ichiro |
author_sort | Inoue, Keiji |
collection | PubMed |
description | 5‐Aminolevulinic acid is a new‐generation photosensitizer with high tumor specificity. It has been used successfully in the diagnosis, treatment, and screening of urological cancers including bladder cancer; specifically, it has been used in photodynamic diagnosis to detect tumors by illuminating the lesion with a specific wavelength of light to produce fluorescence in the lesion after administration of 5‐aminolevulinic acid, in photodynamic therapy, which induces tumor cell death via production of cytotoxic reactive oxygen species, and in photodynamic screening, in which porphyrin excretion in the blood and urine is used as a tumor biomarker after administration of 5‐aminolevulinic acid. In addition to these applications in urological cancers, 5‐aminolevulinic acid–based photodynamic technology is expected to be used as a novel strategy for a large number of cancer types because it is based on a property of cancer cells known as the Warburg effect, which is a basic biological property that is common across all cancers. |
format | Online Article Text |
id | pubmed-8819295 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88192952022-02-09 Current status of photodynamic technology for urothelial cancer Inoue, Keiji Fukuhara, Hideo Yamamoto, Shinkuro Karashima, Takashi Kurabayashi, Atsushi Furihata, Mutsuo Hanazaki, Kazuhiro Lai, Hung Wei Ogura, Shun‐Ichiro Cancer Sci Review Articles 5‐Aminolevulinic acid is a new‐generation photosensitizer with high tumor specificity. It has been used successfully in the diagnosis, treatment, and screening of urological cancers including bladder cancer; specifically, it has been used in photodynamic diagnosis to detect tumors by illuminating the lesion with a specific wavelength of light to produce fluorescence in the lesion after administration of 5‐aminolevulinic acid, in photodynamic therapy, which induces tumor cell death via production of cytotoxic reactive oxygen species, and in photodynamic screening, in which porphyrin excretion in the blood and urine is used as a tumor biomarker after administration of 5‐aminolevulinic acid. In addition to these applications in urological cancers, 5‐aminolevulinic acid–based photodynamic technology is expected to be used as a novel strategy for a large number of cancer types because it is based on a property of cancer cells known as the Warburg effect, which is a basic biological property that is common across all cancers. John Wiley and Sons Inc. 2021-12-02 2022-02 /pmc/articles/PMC8819295/ /pubmed/34750935 http://dx.doi.org/10.1111/cas.15193 Text en © 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Review Articles Inoue, Keiji Fukuhara, Hideo Yamamoto, Shinkuro Karashima, Takashi Kurabayashi, Atsushi Furihata, Mutsuo Hanazaki, Kazuhiro Lai, Hung Wei Ogura, Shun‐Ichiro Current status of photodynamic technology for urothelial cancer |
title | Current status of photodynamic technology for urothelial cancer |
title_full | Current status of photodynamic technology for urothelial cancer |
title_fullStr | Current status of photodynamic technology for urothelial cancer |
title_full_unstemmed | Current status of photodynamic technology for urothelial cancer |
title_short | Current status of photodynamic technology for urothelial cancer |
title_sort | current status of photodynamic technology for urothelial cancer |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819295/ https://www.ncbi.nlm.nih.gov/pubmed/34750935 http://dx.doi.org/10.1111/cas.15193 |
work_keys_str_mv | AT inouekeiji currentstatusofphotodynamictechnologyforurothelialcancer AT fukuharahideo currentstatusofphotodynamictechnologyforurothelialcancer AT yamamotoshinkuro currentstatusofphotodynamictechnologyforurothelialcancer AT karashimatakashi currentstatusofphotodynamictechnologyforurothelialcancer AT kurabayashiatsushi currentstatusofphotodynamictechnologyforurothelialcancer AT furihatamutsuo currentstatusofphotodynamictechnologyforurothelialcancer AT hanazakikazuhiro currentstatusofphotodynamictechnologyforurothelialcancer AT laihungwei currentstatusofphotodynamictechnologyforurothelialcancer AT ogurashunichiro currentstatusofphotodynamictechnologyforurothelialcancer |